Cefpodoxime proxetil

Edina Avdic, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Cefpodoxime proxetil is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 4, 2018